MX2011006527A - Agentes medicinales unidos a dipeptido. - Google Patents

Agentes medicinales unidos a dipeptido.

Info

Publication number
MX2011006527A
MX2011006527A MX2011006527A MX2011006527A MX2011006527A MX 2011006527 A MX2011006527 A MX 2011006527A MX 2011006527 A MX2011006527 A MX 2011006527A MX 2011006527 A MX2011006527 A MX 2011006527A MX 2011006527 A MX2011006527 A MX 2011006527A
Authority
MX
Mexico
Prior art keywords
dipeptide
medicinal agents
linked
physiological conditions
compounds
Prior art date
Application number
MX2011006527A
Other languages
English (en)
Inventor
Richard D Dimarchi
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2011006527A publication Critical patent/MX2011006527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona un elemento de dipéptido de auto rotura no enzimática que se puede unir a agentes medicinales conocidos a través de un enlace de amida. El dipéptido se rompe espontáneamente desde el agente medicinal en condiciones fisiológicas a través de una reacción impulsada por la inestabilidad química Por consiguiente, el elemento de dipéptido provee un medio de unión de diferentes compuestos a agentes medicinales conocidos en donde los compuestos posteriormente se liberan desde el agente medicinal después de un tiempo predeterminado de exposición a condiciones fisiológicas Por ejemplo, el dipéptido se puede unir a un sitio activo de un fármaco para formar un fármaco y/o el dipéptido puede comprender un polímero de depósito para secuestrar una composición inyectable que comprende el complejo en el punto de administració.
MX2011006527A 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido. MX2011006527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13922708P 2008-12-19 2008-12-19
PCT/US2009/068711 WO2010080605A1 (en) 2008-12-19 2009-12-18 Dipeptide linked medicinal agents

Publications (1)

Publication Number Publication Date
MX2011006527A true MX2011006527A (es) 2011-08-17

Family

ID=42316744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006527A MX2011006527A (es) 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido.

Country Status (13)

Country Link
US (1) US20110237493A1 (es)
EP (1) EP2376098A4 (es)
JP (2) JP2012512898A (es)
KR (1) KR20110114568A (es)
CN (1) CN102300580A (es)
AU (1) AU2009335711A1 (es)
CA (1) CA2747195A1 (es)
IL (1) IL213341A0 (es)
MX (1) MX2011006527A (es)
PE (1) PE20120331A1 (es)
RU (1) RU2578591C2 (es)
SG (1) SG172290A1 (es)
WO (1) WO2010080605A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
JP5771005B2 (ja) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
PE20100056A1 (es) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp Analogos de glucagon como agonistas gip
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
JP2012512903A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
IN2012DN00377A (es) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2011094337A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
MX2012013005A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g.
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
JP2013540102A (ja) 2010-06-24 2013-10-31 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
KR20130083843A (ko) * 2010-06-24 2013-07-23 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 디펩티드 연결된 약제
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
PE20140724A1 (es) 2011-06-22 2014-07-10 Univ Indiana Res & Tech Corp Coagonistas del receptor de glucagon/glp-1
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
CN103172726B (zh) * 2011-12-22 2017-06-13 杭州淳泰科技有限公司 胰泌素类似物及其制备方法和用途
US9452225B2 (en) 2012-03-01 2016-09-27 Novo Nordisk A/S GLP-1 prodrugs
JP6311708B2 (ja) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
AU2014241743B2 (en) 2013-03-14 2018-07-05 Indiana University Research And Technology Corporation Insulin-incretin conjugates
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
WO2017210489A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. Compounds
JP2023527356A (ja) * 2020-05-26 2023-06-28 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 副甲状腺機能低下症を処置するためのｐｔｈ類似体
CN116157143A (zh) 2020-07-22 2023-05-23 诺和诺德股份有限公司 适合于口服递送的glp-1和gip受体的共激动剂
TW202218684A (zh) 2020-11-06 2022-05-16 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023217744A1 (en) 2022-05-10 2023-11-16 Novo Nordisk A/S Prodrugs of glp-1 polypeptide and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740385A (en) * 1970-05-07 1973-06-19 M Ondetti N-terminal derivatives of secretin
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
US4741897A (en) * 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
WO2000058360A2 (en) * 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
AUPQ661800A0 (en) * 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
US6967202B2 (en) * 2000-08-04 2005-11-22 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
US7052686B2 (en) * 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
JP2005502322A (ja) * 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7238656B2 (en) * 2001-08-29 2007-07-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
CA2468100A1 (en) * 2001-12-20 2003-07-03 Eli Lilly And Company Insulin molecule having protracted time action
FR2842209B1 (fr) * 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
SI1605897T1 (sl) * 2003-03-19 2012-11-30 Lilly Co Eli Polietilen glikol povezane GLP spojine
WO2004089280A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
BRPI0414539B8 (pt) * 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2006287531A1 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of T3 and T4 with enhanced bioavailability
CA2646598C (en) * 2006-03-21 2014-08-19 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
MX2009002523A (es) * 2006-09-08 2009-03-20 Ambrx Inc Polipeptido de plasma humano modificado o andamios fc y sus usos.
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
NZ578948A (en) * 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
AU2009210570B2 (en) * 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
JP2012512903A (ja) * 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド系グルカゴンスーパーファミリーペプチドプロドラッグ

Also Published As

Publication number Publication date
JP2016028082A (ja) 2016-02-25
EP2376098A4 (en) 2014-06-11
CA2747195A1 (en) 2010-07-15
RU2011129764A (ru) 2013-01-27
US20110237493A1 (en) 2011-09-29
IL213341A0 (en) 2011-07-31
WO2010080605A1 (en) 2010-07-15
AU2009335711A1 (en) 2010-07-15
KR20110114568A (ko) 2011-10-19
JP2012512898A (ja) 2012-06-07
CN102300580A (zh) 2011-12-28
EP2376098A1 (en) 2011-10-19
PE20120331A1 (es) 2012-04-14
RU2578591C2 (ru) 2016-03-27
SG172290A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
MX2011006527A (es) Agentes medicinales unidos a dipeptido.
WO2011163594A3 (en) Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CR11441A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
NZ597108A (en) Prodrugs of nh-acidic compounds
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
DK2579874T3 (da) Injicerbar, flydende sammensætning omfattende buprenorphin
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
CR20110110A (es) Composicion farmaceutica
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
MX2009013835A (es) Forma de dosis estabilizada de picoplatino.
MA34296B1 (fr) Composition retard injectable antipsychotique
NO20092998L (no) Flytende formuleringer, som danner dermal film, for frigjoring av legemidler til huden
AR043423A1 (es) Sistema de liberacion controlada
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
CY1112637T1 (el) Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης
MX2013012206A (es) Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas.
NO20083928L (no) Anvendelse av TPO-peptidforbindelser og farmasoytiske sammensetninger i behandling av anemi

Legal Events

Date Code Title Description
FG Grant or registration